Dowpharma, Abbott Enter Technology Pact

Abbott has entered into a commercial license agreement with Dowpharma for its Pfenex Expression Technology, a Pseudomonas-based technology for biologic production. Abbott’s product is a proprietary protein for which the company has already developed a high-yield production strain and a fully scalable process. Dow will transfer the production strain to Abbott and support its regulatory filing. Under the agreement, Abbott will have a non-exclusive license to use Pfenex for the development and manufacture of the drug.

“This agreement with Abbott is yet another validation in a long line of agreements by the pharmaceutical industry that our technologies continue to deliver valued solutions. We are pleased to be working with Abbott to help fulfill its future protein production needs as part of this commercial license agreement,” said Nick Hyde, global business director for Dowpharma. “Proteins produced by Pfenex Expression Technology are now in human clinical trials and the system consistently delivers high quality protein faster than traditional expression systems.”